ResMed’s new product gets US FDA clearance


The United States Food and Drug Administration has cleared ResMed’s new AirMini sleep apnea treatment product.

ResMed, established in 1989, made the announcement in San Francisco at the 35th annual J.P. Morgan Healthcare Conference.

“ResMed AirMini is the portable travel CPAP patients and home medical equipment providers have been waiting for, and we look forward to bringing it to market later this year,” ResMed CEO, Mick Farrell, said in a statement.


The company employs over 5,000 worldwide and pioneered the treatment of sleep apnea through continuous positive airway pressure (CPAP) devices. The AirMini is designed as a secondary machine, for use while travelling, and fits within carry-on luggage.


Leave a Reply